Lyell Immunopharma, Inc.
Company Stats
- Market Cap
- $239.9M
- as of Sep 30, 2026
- Shares Outstanding
- 24.5M
- Free Float
- 50.6%
Income Statement
- Revenue
- $36,000
- Operating Income
- -$269.4M
- Net Income
- -$274.4M
- EBITDA
- -$257.9M
- Non-cash Impairment
- $1.4M
- Revenue Growth, 3Y
- -92.5%
- FCF Margin, 3Y Avg
- -271288.3%
- FCF Margin, Worst Year
- -418900.0%
Cash Flow
- Free Cash Flow
- -$150.8M
- FCF Yield
- -62.9%
- Owner FCF Yield
- -80.3%
Balance Sheet
- Cash & Equivalents
- $60.2M
Returns & Capital
- SBC, 3Y Avg
- $40.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $36,000 | -$150.8M | -418900.0% |
| FY2024 | $61,000 | -$162.9M | -266980.3% |
| FY2023 | $130,000 | -$166.4M | -127984.6% |
| FY2022 | $84.7M | -$193.8M | -228.9% |
| FY2021 | $10.7M | -$191.8M | -1800.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges